Full Press Release Details
Eidos Therapeutics To Present Data On Its Potential Treatment For Transthyretin Amyloidosis At The American Heart Association.
BBIO
Eidos Therapeutics To Present Data On Its Potential Treatment For Transthyretin Amyloidosis At The American Heart Association
Key Takeaway: Eidos Therapeutics To Present Data On Its Potential Treatment For Transthyretin Amyloidosis At The American Heart Association
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis